PL212380B1 - [2- or 4-(methyl)-6-xantonyloxy] alkane acides and their derivatives - Google Patents

[2- or 4-(methyl)-6-xantonyloxy] alkane acides and their derivatives

Info

Publication number
PL212380B1
PL212380B1 PL363979A PL36397903A PL212380B1 PL 212380 B1 PL212380 B1 PL 212380B1 PL 363979 A PL363979 A PL 363979A PL 36397903 A PL36397903 A PL 36397903A PL 212380 B1 PL212380 B1 PL 212380B1
Authority
PL
Poland
Prior art keywords
compounds
derivatives
methyl
xantonyloxy
acides
Prior art date
Application number
PL363979A
Other languages
Polish (pl)
Other versions
PL363979A1 (en
Inventor
Henryk Marona
Tadeusz Librowski
Original Assignee
Univ Jagiellonski Collegium Medicum
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Jagiellonski Collegium Medicum filed Critical Univ Jagiellonski Collegium Medicum
Priority to PL363979A priority Critical patent/PL212380B1/en
Publication of PL363979A1 publication Critical patent/PL363979A1/en
Publication of PL212380B1 publication Critical patent/PL212380B1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

Związki o ogólnym wzorze 1 otrzymane sposobem wynalazku wykazują działanie przeciwobrzękowe i przeciwbólowe, w związku z tym mogą znaleźć zastosowanie w leczeniu stanów zapalnych (stany zwyrodnieniowe kręgosłupa, choroby reumatyczne, bóle ostre i przewlekłe).The compounds of the general formula I obtained by the method of the invention show an anti-edema and analgesic effect, therefore they can be used in the treatment of inflammatory conditions (degenerative conditions of the spine, rheumatic diseases, acute and chronic pain).

Związki 3 (Tabela 1) i 8 (Tabela 2) o ogólnym wzorze 1 można uzyskać z 4- lub 2-(metylo)-6-(hydroksy)-ksantonu (związki 1 i 7), który poddaje się reakcji O-alkilowania przy użyciu odpowiednich chlorowcokwasów w środowisku alkoholowym (metanol lub etanol) w obecności bezwodnego K2CO3 lub estrowych pochodnych chlorowcokwasów w środowisku DMF w obecności bezwodnego K2CO3, a nastę pnie alkalicznej hydrolizie surowych estrów.Compounds 3 (Table 1) and 8 (Table 2) of general formula 1 can be obtained from 4- or 2- (methyl) -6- (hydroxy) -xanthone (compounds 1 and 7) which is subjected to an O-alkylation reaction at using the appropriate halogen acids in an alcoholic medium (methanol or ethanol) in the presence of anhydrous K2CO3 or ester derivatives of halogen acids in DMF in the presence of anhydrous K2CO3, followed by alkaline hydrolysis of the crude esters.

Kwas 2-[4-(metylo)-6-ksantonylooksy]-2-metylopropanowy (związek 5, Tabela 1), uzyskuje się metodą Linka w reakcji 4-(metylo)-6-(hydroksy)-ksantonu z chloroformem i acetonem w środowisku zasadowym (NaOH). Kwasy 3, 5 (Tabela 1) i 8 (Tabela 2) scharakteryzowano poprzez odpowiednie estrowe pochodne (zw. 2, 4, 6 - Tabela 1) i 9 (Tabela 2). Wydzielony w reakcji związek 10 (Tabela 2) poprzez amonolizę w metanolowym roztworze amoniaku przekształcono dla celów badawczych w zwią zek 11 (Tabela 2).2- [4- (methyl) -6-xanthonyloxy] -2-methylpropanoic acid (compound 5, Table 1), obtained by Link's method by reacting 4- (methyl) -6- (hydroxy) -xanthone with chloroform and acetone in alkaline environment (NaOH). Acids 3, 5 (Table 1) and 8 (Table 2) are characterized by the respective ester derivatives (Comp. 2, 4, 6 - Table 1) and 9 (Table 2). Compound 10 (Table 2) isolated in the reaction was converted by ammonolysis in methanolic ammonia solution, for research purposes, into compound 11 (Table 2).

Charakterystykę związków o ogólnym wzorze 1 podano w tabeli 3.Characteristics of compounds of general formula I are given in Table 3.

Związki o ogólnym wzorze 1, zwłaszcza związki 3, 5 i 8 wykazują korzystne działanie przeciwobrzękowe i/lub przeciwbólowe. Stosowane w dawkach w zakresie 50 - 200 mg hamują narastanie obrzęku karageninowego w metodzie Wintera oraz podwyższają próg reakcji bólowej w metodzie Randalla i Selitto. Dla najaktywniejszych związków wykonano ocenę ich wpływu na błonę śluzową żołądka po jednorazowym podaniu wg metody Komatsu. Związki te wykazały zupełny brak działania ulcerogennego na śluzówką żołądka szczura, w przeciwieństwie do użytych związków odniesienia takich jak indometacyna czy ketoprofen, które silnie uszkadzały śluzówkę żołądka u badanych zwierząt. Dla porównania wyników, jako związków odniesienia, użyto aspiryny, ketoprofenu, indometacyny oraz piroksikamu. Badane związki charakteryzują się nieco niższą aktywnością przeciwobrzękową niż aspiryna, indometacyna czy ketoprofen, natomiast wykazują większą niż piroksikam aktywność przeciwbólową. Z dotychczas przebadanych struktur związki 3, 5 i 8 zakwalifikowano do poszerzonych badań farmakologicznych.The compounds of formula I, in particular compounds 3, 5 and 8, have a beneficial anti-edema and / or analgesic effect. When used in doses in the range of 50-200 mg, they inhibit the growth of carrageenan edema in the Winter method and increase the pain reaction threshold in the Randall and Selitto method. The most active compounds were assessed for their influence on the gastric mucosa after a single administration according to the Komatsu method. These compounds showed a complete lack of an ulcerogenic effect on the rat gastric mucosa, in contrast to the reference compounds used, such as indomethacin or ketoprofen, which strongly damaged the gastric mucosa in the test animals. For comparison of results, aspirin, ketoprofen, indomethacin and piroxicam were used as reference compounds. The tested compounds are characterized by a slightly lower anti-edema activity than aspirin, indomethacin or ketoprofen, while they exhibit greater analgesic activity than piroxicam. From the structures tested so far, compounds 3, 5 and 8 were qualified for extended pharmacological tests.

PL 212 380 B1PL 212 380 B1

Tabela 3. Wybrane pochodne ksantonu i dane charakterystyczneTable 3. Selected xanthon derivatives and characteristic data

PL 212 380 B1PL 212 380 B1

Tabela 3. Wybrane pochodne ksantonu i dane charakterystyczne c.d.Table 3. Selected xanthon derivatives and characteristic data continued

PL 212 380 B1PL 212 380 B1

Claims (4)

1. Nowe związki, pochodne ksantonu o ogólnym wzorze 1, w którym R oznacza: resztę metylową w położeniu 4; natomiast Z oznacza: grupę typu:1. Novel compounds, xanthone derivatives of the general formula in which R is: a methyl residue in position 4; while Z means: a group of the type: - CH(CH3)CO2H;- CH (CH3) CO2H; - C(CH3)2CO2H- C (CH3) 2CO2H 2. Estrowe pochodne (związki 3, 5 i 7) uzyskane ze związków wg zastrzeżenia 1.2. Ester derivatives (compounds 3, 5 and 7) obtained from the compounds according to claim 1. 3. Nowe związki, pochodne ksantonu o ogólnym wzorze 1, w którym R oznacza: resztę metylową w położeniu 2; natomiast Z oznacza grupę typu:3. New compounds, xanthone derivatives of the general formula I, in which R represents: a methyl residue in position 2; while Z stands for a group of the type: - CH2CO2H;- CH2CO2H; - CH2CO2CH3;- CH2CO2CH3; - CH(CH3)CO2CH3;- CH (CH3) CO2CH3; - CH(CH3)CO2NH2- CH (CH3) CO2NH2 RysunkiDrawings T a b e l a 1.T a b e l a 1. Związek R Z 1Relationship R WITH 1 4-CH3 H 2 4-CH3 CH2CO2CH3 3 4-CH3 CH(CH3)CO2H 4 4-CH3 CH(CH3)CO2CH3 5 4-CH3 C(CH3)2CO2H 6 4-CH3 C(CH3)2CO2C2H54-CH3 H. 2 4-CH3 CH2CO2CH3 3 4-CH3 CH (CH3) CO2H 4 4-CH3 CH (CH3) CO2CH3 5 4-CH3 C (CH3) 2CO2H 6 4-CH3 C (CH3) 2CO2C2H5 T a b e l a 2 Związek R Z 7 2-CH3 H 8 2-CH3 CH2CO2H 9 2-CH3 CH2CO2CH3 10 2-CH3 CH(CH3)CO2CH3 11 2-CH3 CH(CH3)CONH2T a b e l a 2 Relationship R WITH 7 2-CH3 H. 8 2-CH3 CH2CO2H 9 2-CH3 CH2CO2CH3 10 2-CH3 CH (CH3) CO2CH3 11 2-CH3 CH (CH3) CONH2
PL363979A 2003-12-10 2003-12-10 [2- or 4-(methyl)-6-xantonyloxy] alkane acides and their derivatives PL212380B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL363979A PL212380B1 (en) 2003-12-10 2003-12-10 [2- or 4-(methyl)-6-xantonyloxy] alkane acides and their derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL363979A PL212380B1 (en) 2003-12-10 2003-12-10 [2- or 4-(methyl)-6-xantonyloxy] alkane acides and their derivatives

Publications (2)

Publication Number Publication Date
PL363979A1 PL363979A1 (en) 2005-06-13
PL212380B1 true PL212380B1 (en) 2012-09-28

Family

ID=35768706

Family Applications (1)

Application Number Title Priority Date Filing Date
PL363979A PL212380B1 (en) 2003-12-10 2003-12-10 [2- or 4-(methyl)-6-xantonyloxy] alkane acides and their derivatives

Country Status (1)

Country Link
PL (1) PL212380B1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL450653A1 (en) * 2024-12-20 2026-06-22 Uniwersytet Jagielloński New xanthone derivative for use in treatment or prevention of cardiovascular diseases

Also Published As

Publication number Publication date
PL363979A1 (en) 2005-06-13

Similar Documents

Publication Publication Date Title
Teng et al. Structure–activity relationship study of novel necroptosis inhibitors
US6727281B2 (en) Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives
JP5048017B2 (en) Substituted phenylalkanoic acid derivatives and uses thereof
IL187713A (en) 3-aminocarbazole compounds, pharmaceutical compositions containing the same and method for the preparation thereof
JPH0755921B2 (en) Amides
CZ20021591A3 (en) 5-Aryl-1H-1, 2, 4-triazoles functioning as cyclooxygenase-2y inhibitors and pharmaceutical compositions in which these compounds are comprised
EP2049482B1 (en) Positively charged water-soluble prodrugs of aryl- and heteroarylacetic acids with very fast skin penetration rate
Abouzid et al. Design, synthesis, and evaluation of anti-inflammatory and ulcerogenicity of novel pyridazinone derivatives
JPS61137878A (en) 1-heteroaryl-4-aryl-pyrazolone-5-ones for drug
CA2476056A1 (en) Novel 1,2,3-substituted indolizine derivatives, inhibitors of fgfs, method for making same and pharmaceutical compositions containing same
ITMI962385A1 (en) PHARMACOLOGICALLY ACTIVE DIARYL-CYCLOMETHYLENPYRAZOLES, PROCEDURE FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
US5288750A (en) Substituted β-diketones
ULUDAĞ et al. Stable ester and amide conjugates of some NSAIDs as analgesic and antiinflammatory compounds with improved biological activity
US20080214646A1 (en) Novel Nsaids Possessing a Nitric Oxide Donor Diazen-1-Ium-1,2-Diolate Moiety
JP2011516502A (en) Novel compounds derived from taurine, methods for their preparation and pharmaceutical compositions containing them
IE882304L (en) Naphthalenepropionic acid derivatives
Li et al. In vitro and in vivo profile of 2-(3-di-fluoromethyl-5-phenylpyrazol-1-yl)-5-methanesulfonylpyridine, a potent, selective, and orally active canine COX-2 inhibitor
JP5395905B2 (en) Anti-inflammatory compounds
Halen et al. Substituted aminoalcohol ester analogs of indomethacin with reduced toxic effects
AU2013206218A1 (en) Positively charged water-soluble prodrugs of aryl- and heteroarylpropionic acids with very fast skin penetration rate
CS216206B2 (en) Method of making the derivatives of the diphenylpyrazole
CN105348169B (en) A kind of acrylamide of inhibitors of histone deacetylase (E) 3 (2 (base of 11 hydrogen indoles of (4 chlorobenzene formacyl) 5 methoxyl group, 2 methyl 3) acetylamino) N hydroxyls fourth 2 and its preparation method and application
Mo et al. Novel 5-aminosalicylic acid NSAID conjugates: synthesis; pharmacological and toxicological properties
CN105367479A (en) Histone deacetylase inhibitor 2-(1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1 hydro-indole-3-yl-N-(2-(hydroxyamino)-2-ketoacyl) acetamide and preparation method and application thereof
Chandak et al. Synthesis and investigation of anti-inflammatory activity of novel nitric oxide donating hybrid drugs

Legal Events

Date Code Title Description
LAPS Decisions on the lapse of the protection rights

Effective date: 20131210